What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

This review evaluates the efficacy and safety of crizanlizumab for treating sickle cell disease by analyzing relevant studies.

December 8, 2025BloodOpen Access

Efficacy and safety of crizanlizumab in sickle cell disease : A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

ANAmmar NasirKhyber Teaching Hospital RBRayyan Mohammad Makki BakhshFoundation University Medical College AKAmal KhanFoundation University Medical College

Discussion

Member takes

Implication

Meta-analysis finds that crizanlizumab does not significantly reduce VOCs or adverse events in sickle cell disease patients, indicating further research is needed.

Key Points

This review evaluates the efficacy and safety of crizanlizumab for treating sickle cell disease by analyzing relevant studies.
Systematic review and meta-analysis conducted following PRISMA guidelines.
Literature review included randomized controlled trials and observational studies comparing crizanlizumab with placebo or standard therapy.
Primary outcome was the annual rate of vaso-occlusive crises; secondary outcomes included opioid use, adverse events, and mortality.
No significant reduction in the frequency of vaso-occlusive crises was observed with crizanlizumab compared to placebo (RR = 0.97, p = 0.51).
Higher incidence of adverse events in the crizanlizumab group, not statistically significant (RR = 1.20, p = 0.31).
No significant difference in serious adverse events or pooled mortality data due to inadequate reporting.

Cite This Study

Nasir et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2de https://doi.org/10.1182/blood-2025-6498

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis finds that crizanlizumab does not significantly reduce VOCs or adverse events in sickle cell disease patients, indicating further research is needed.

Efficacy and safety of crizanlizumab in sickle cell disease : A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of crizanlizumab in sickle cell disease : A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider